A Smart + Strong Site
Subscribe to:
POZ magazine

Back to home » Treatment News » Top Stories

Most Popular Stories
Undetectable Viral Load Essentially Eliminates Transmission Risk in Straight Couples
FDA Approves New Single-Tablet HIV Regimen, Triumeq
Life Expectancy for Young People With HIV Is Nearly Normal
A 15-Year Jump in Life Expectancy for People With HIV
Scientists Devise Method of Snipping HIV From Immune Cells
Monkey HIV Vaccine Success Opens Door for Human Trials
HIV Combo Pill Less Toxic Thanks to New Form of Tenofovir
What's That Mean?
(just double-click it!)

If you don't understand one of the words in this article, just double-click it. A window will open with a definition from mondofacto's On-line Medical Dictionary. If the double-click feature doesn't work in your browser, you can enter the word below:

Most Popular Lessons
Aging & HIV
The HIV Life Cycle
Herpes Simplex Virus
Syphilis & Neurosyphilis
Treatments for Opportunistic Infections (OIs)
What is AIDS & HIV?
More News

Have medical or treatment news about HIV? Send press releases, news tips and other announcements to news@aidsmeds.com.

Click here for more news


January 30, 2012

Alcohol Treatment Boosts Hep C Cure Rates Among Drinkers

People who drink—even heavily—can successfully undergo treatment for hepatitis C virus (HCV) if they’re provided with individualized, multidisciplinary care that also addresses their alcohol use, according to a study published in the February 2012 issue of Journal of Hepatology.  

Caroline Le Lan, MD, and her colleagues in Brittany, France, treated 73 alcohol-dependent patients for both hepatitis C and addiction, between September 2002 and February 2008. Their treatment outcomes were compared to a matched group of non-drinkers. Although overall cure rates were similar (48 percent versus 49 percent for non-drinkers), people who drank excessively during HCV treatment—defined as 21 or more drinks per week for men, 14 or more drinks per week for women, or at least four drinks at a time, at least twice—were less likely to be cured than those who drank less or were abstinent.  

Excessive alcohol consumption—50 grams (3.5 glasses of wine) or more a day—is known to worsen liver damage from hepatitis C. Drinking also increases hepatitis C viral load, and it may make adherence to HCV treatment difficult. For these reasons, the American Association for the Study of Liver Diseases (AASLD) recommends that HCV treatment decisions for people actively using alcohol be determined on a case-by-case basis, with an emphasis on patient participation in an alcohol support program.  

According to the AASLD’s HCV Practice Guidelines, “[I]t seems reasonable to recommend either the complete suspension of alcohol intake while on treatment or restricting its use to an occasional drink during the course of the treatment.”

There is very little information on HCV treatment outcomes among moderate or excessive drinkers. “Doctors are reluctant to treat alcoholic patients because they fear that these patients may experience more side effects and have poor adherence and that heavy alcohol consumption may worsen antiviral treatment outcomes,” said Lan and her colleagues, noting that it may not be possible for every alcohol-dependent patient to reduce, or stop, alcohol consumption, either before or during HCV treatment.

Before starting treatment, study participants were seen by a hepatologist, counseled about risks and benefits of HCV treatment, and evaluated by an addiction specialist who provided individualized counseling. Although study participants were encouraged to reduce or stop alcohol consumption, they were not disqualified if they continued to drink. Excessive drinking was reported by 62 percent of participants when they started HCV treatment; their alcohol consumption ranged from 30 to 98 drinks per week, and the majority had a history of injection drug use. Only 34 percent had been abstinent for less than three months.

Pegylated interferon and ribavirin were administered for six to 12 months, according to HCV genotype and response to treatment. Most were first-time treatment takers. Thirty-four percent had HCV genotype 3, and 42 percent had a low hepatitis C viral load—both of which are associated with higher likelihood of achieving a sustained virological response (SVR), or viral cure. In contrast, 34 percent had serious liver damage, which reduces the odds of being cured.

Overall, 65 percent of abstinent patients were cured, compared with 52 percent of moderate drinkers and 33 percent of heavy drinkers. People with a low pre-treatment HCV viral load were more likely to be cured, as were study participants with a history of severe drug addiction. “This indicates that difficulties with drugs, such as pursuing injections despite substitution treatment, are not a reason to exclude patients from treatment,” Lan and her colleagues wrote.

A total of six participants discontinued treatment, and another six missed some of their study visits. Treatment adherence was associated with family and social status, and duration of abstinence from alcohol before treatment.

“The paradox is that alcoholic patients, who have the highest potential to progress to severe liver disease, are excluded from treatment without any published evidence,” said the authors. There was an unexpected benefit to combining treatment for HCV and alcohol dependence: a third of patients, half of them heavy drinkers, stopped drinking during HCV treatment and remained abstinent afterward. Lan’s group concluded, “Treating alcoholic patients was feasible and led to viral eradication and durable alcohol cessation in a number of them.”

Search: hepatitis C, treatment, alcohol, SVR, cure, addiction, sobriety

Scroll down to comment on this story.


(will display; 2-50 characters)


(will NOT display)


(will display; optional)

Comment (500 characters left):

(Note: The AIDSmeds team reviews all comments before they are posted. Please do not include ":" "@" "<" ">" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules

Show comments (1 total)

[Go to top]

Quick Links
About HIV and AIDS
The Cure
Lab Tests
Clinical Trials
HIV Meds
Starting Treatment
Switching Treatment
Drug Resistance
Side Effects
Hepatitis & HIV
Women & Children
Fact Sheets
Treatment News
Community Forums
Conference Coverage
Health Services Directory
POZ Magazine
AIDSmeds on Twitter

Conference Coverage

XX International AIDS Conference
(AIDS 2014)
Melbourne, Australia
July 20 - 25, 2014

21st Conference on Retroviruses and Opportunistic Infections
(CROI 2014)
Boston, MA
March 3 - 7, 2014

7th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention
(IAS 2013)
Kuala Lumpur, Malaysia
June 30 - July 3, 2013

more conference coverage

[ about AIDSmeds | AIDSmeds advisory board | our staff | advertising policy | advertise/contact us]
© 2016 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.